Browse All

Current Filters

CLEAR FILTER x

TITLE

Paramagnetic rim lesions predict the development of clinical MS in radiologically isolated syndrome: results from a prospective cohort study

Author:Oh, Jiwon   Lim, Timothy   Suthiphosuwan, Suradech   Espiritu, Adrian   Guenette, Melanie   Bharatha, Aditya   Sati, Pascal   Absinta, Martina   Reich, Daniel   

Session Name:S27: MS Neuroimaging  

Topic:MS and Inflammatory Disease  

Program Number:S27.003  

Author Institution:St Michael's Hospital, Toronto, ON, Canada  St Michael’s Hospital, Unity Health, Toronto, ON, Canada  BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada  Cedars Sinai, Los Angeles, CA  National Institutes of Health, Bethesda, MD  National Institutes of Health, Neuroimmunology Branch, NINDS, Bethesda, MD  

Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial

Author:Traboulsee, Anthony   Fox, Robert   Arnold, Douglas   Syed, Sana   Orogun, Larry   Dukovic, Deborah   Turner, Timothy   Reich, Daniel   Oh, Jiwon   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.006  

Author Institution:University of British Columbia, Vancouver, BC, Canada  Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  National Institute of Neurological Disorders and Stroke, Bethesda, MD  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada  

MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results

Author:Reich, Daniel   Traboulsee, Anthony   Syed, Sana   Xu, Zhixing   Turner, Timothy   Arnold, Douglas   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.012  

Author Institution:National Institute of Neurological Disorders and Stroke, Bethesda, MD  University of British Columbia, Vancouver, BC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  

MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study

Author:Fox, Robert   Oh, Jiwon   Arnold, Douglas   Syed, Sana   Xu, Zhixing   Turner, Timothy   Traboulsee, Anthony   Reich, Daniel   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.017  

Author Institution:Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH  St Michael's Hospital, University of Toronto, Toronto, ON, Canada  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  University of British Columbia, Vancouver, BC, Canada  National Institute of Neurological Disorders and Stroke, Bethesda, MD  

Loss of gyrification is associated with disability progression in multiple sclerosis

Author:Dos Santos Silva, Jonadab   La Rosa, Francesco   Mullins, William A   Parvathaneni, Prasanna   Maranzano, Josefina   Reich, Daniel   Beck, Erin   

Session Name:P10: MS Neuroimaging 1  

Topic:MS and Inflammatory Disease  

Program Number:P10.006  

Author Institution:Icahn School of Medicine at Mount Sinai, New York, NY  National Institutes of Health, Bethesda, MD  McGill University, Montreal Neurological Institute, Montreal, QC, Canada  National Institutes of Health, Neuroimmunology Branch, NINDS, Bethesda, MD